Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis

The transaction builds on Quest Diagnostics' leadership in oncology and subspecialized pathology services. It will support PathAI's strategy to amplify its investments in AI technology and expand its software and algorithm business. AI in pathology offers numerous advantages, including improved accuracy, increased efficiency and enhanced patient care. Furthermore, the growing demand for misdiagnosis, funding initiatives for improving patient care quality and increasing emphasis on cost control and efficienc ...